Chemotherapy

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART
DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special
(Storage Prior to Use, With: Stability Precautions/Notes
Manufacturer, Preservative
Status)
Leucovorin
1 3 3
50 mg/5 mL N/A 10 mg/mL 50 mg: discard syringe 7 d F,
2 3,4
500 mg/50 mL unused portion 48 h RT
(Hospira)
(F)(PFL) 500 mg:
1 1
no preservative 8h 0.05-10 mg/mL NS, D5W, LR,
NS, D5W, Ringer’s, Ringer’s:
1,2 1
LR, D10W, D5NS 24 h RT
(e.g., 50-250 mL*) D10W, D5-NS:

1
8 h RT
BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 1/39

Activation Date: 2 March 2006
Revised Date: 1 January 2019
Status)
Leucovorin
1 6,7
50 mg/5 mL N/A 10 mg/mL discard unused syringe 8h
1
500 mg/50 mL portion
(Teva)
(F)(PFL)
5 8
no preservative 0.4 - 4.8 mg/mL NS, 72 h F, RT
8
D5W
(e.g., 50-250 mL*)
0.06 - 0.4 mg/mL NS, NS:

5 5
D5W 24 h RT
D5W:
5
12 h RT
0.06 - 1 mg/mL Ringer’s, LR:

5
Ringer’s, Lactated 24 h RT
Ringer’s, D10W,
5
D10NS D10W:
5
12 h RT
D10NS:
5
6 h RT

Status)
Leucovorin
9 9 9
50 mg/5 mL N/A 10 mg/mL 8h syringe 8 h RT
500 mg/50 mL
(Pfizer)
(F)(PFL) 0.05 – 10 mg/mL NS, NS, D5W, LR,
9
no preservative D5W, LR, Ringer’s, Ringer’s:
9 9
D10W, D5NS 24 h RT
(e.g., 50-250 mL*) D10W, D5NS:

9
8 h RT
Mechlorethamine
10 10
10 mg do NOT use if 1 mg/mL use within 4 h of syringe complete
(Ovation/Merck) discoloured or water reconstitution administration within
7,11
(RT,PFL) droplets form in vial RT 4 h of reconstitution
10 7,10,11
no preservative before RT
10
reconstitution
10
10 mL SWI or NS
10,12
100 mL NS complete
record time of administration within
reconstitution 4 h of reconstitution
7,10,12
RT

Status)
Melphalan
13 13
50 mg 10mL supplied 5 mg/mL 2 h RT 0.1 – 0.45 mg/mL in complete
13 13
(GSK) diluent NS only administration within
(RT)(PFL) do NOT 60 min from time of
13
no preservative immediately after refrigerate (e.g., greater than 45 initial reconstitution at
11
adding diluent, mg and less than or RT
13
shake vigorously equal to 110 mg in
250 mL NS)*
record time of
reconstitution
Mesna
14
400 mg/4 mL N/A 100 mg/mL discard unused greater than 1 mg/mL complete
14
1000 mg/10 mL portion in D5W, D5½NS, NS, administration within
14-16 14
(Baxter) (use filter needle to LR 24 h RT
(RT) withdraw from
14
no preservative ampoule)
Mesna
14 14
1000 mg/10 mL N/A 100 mg/mL 8 days RT greater than 1 mg/mL complete
5000 mg/50 mL in D5W, D5½NS, NS, administration within
14-16 14
(Baxter) (vial may be LR 24 h RT
(RT) punctured up to 4
14 14
preservative times)
Mesna
17 17,18 17
1000 mg/10mL N/A 100 mg/mL 14 d RT,F greater than or equal 24 h RT, 48 h F
(Fresenius Kabi) to 1 mg/mL in NS or
19
(RT) D5W
17
preservative

Status)
Methotrexate
20
50 mg/2mL N/A 25 mg/mL 50mg: syringe use within 8 h RT of - for high-dose
20
500 mg/20mL discard unused initial puncture regimens (e.g., 1-
20 2
1 g/40mL portion 12 g/m as a single
21-25
2.5 g/100 mL dose) : use
(Pfizer/Hospira) 500 mg, 1 g, or 0.4–2 mg/mL NS, use within 24 h RT of preservative-free
20 20 20
(RT)(PFL) 2.5 g: D5W initial puncture methotrexate
20 20
no preservative 8 h RT - do not use for IT
(100 mL* NS, D5W) **(PFL) injection
high dose use within 24 h RT of

2 20
(e.g., 1-12 g/m as a initial puncture
21-25
single dose) : 1000
mL* NS **(PFL)
Methotrexate
20 29
IT Injection N/A 25 mg/mL discard unused qs to 6 mL with use within 4 h of initial - auxiliary info :
20 18
Only preservative free portion preservative free puncture “IT”
27,28
methotrexate may be NS - label to include
administered by the route in full (i.e.,
26
intrathecal route INTRATHECAL
50 mg/2mL injection) attached
(Pfizer/Hospira) to both syringe and
29
(RT)(PFL) outer ziplock bag
20
no preservative

Status)
Methotrexate
20 18,20 18
50 mg/2mL N/A 25 mg/mL 14 d F syringe 14 d F - contains benzyl
20
500 mg/20mL alcohol
(Pfizer/Hospira) - do NOT use for
(RT)(PFL) 0.4–2 mg/mL NS, 24 h RT
20 high-dose
20
preservative D5W
20 regimens (e.g., 1-
2
12 g/m as a single
20
(100 mL* NS, D5W) dose)
- do NOT use for IT
20
injection
Mitomycin
30 30 30 30
20 mg 40 mL SWI 0.5 mg/mL 6 h RT, 72 h F syringe 6 h RT, 72 h F
(Accord)
30 30 30
(RT)(PFL) shake well **(PFL) **(PFL)
30
no preservative
Mitomycin
30 30 30 30
intravesical 40 mL SWI 0.5 mg/mL 6 h RT, 72 h F syringe 6 h RT, 72 h F
20 mg
30 30 30
(Accord) shake well **(PFL) **(PFL)
(RT)(PFL)
30
no preservative
31 31
10 mL SWI 2 mg/mL use immediately syringe use immediately after - may precipitate
after preparation preparation to prevent due to low
30 32 32,33
shake well to prevent precipitation solubility
32
precipitation - do NOT
32
refrigerate

Status)
Mitomycin
30 30 30 30
intraperitoneal 40 mL SWI 0.5 mg/mL 6 h RT, 72 h F 0.02-0.04 mg/mL NS:
30
20 mg 3 h RT, 18 h F
30 30 30
(Accord) shake well **(PFL) NS, sodium lactate
(RT)(PFL) sodium lactate:
30 30
no preservative 3 h RT, 6 h F
Mitomycin
34 34 34 34
20 mg 40 mL SWI 0.5 mg/mL 6 h RT, 72 h F syringe 6 h RT, 72 h F
(Teva/Novopharm)
34 34 34
(RT)(PFL) shake well **(PFL) **(PFL)
34
no preservative
Mitomycin
34 34 34 34
intravesical 40 mL SWI 0.5 mg/mL 6 h RT, 72 h F syringe 6 h RT, 72 h F
20 mg
34 34 34
(Teva/Novopharm) shake well **(PFL) **(PFL)
(RT)(PFL)
34
no preservative
31 31
10 mL SWI 2 mg/mL use immediately syringe use immediately after - may precipitate
after preparation preparation to prevent due to low
34 32 32,33
shake well to prevent precipitation solubility
32
precipitation - do NOT
32
refrigerate
Mitomycin
34 34 34 34
intraperitoneal 40 mL SWI 0.5 mg/mL 6 h RT, 72 h F 0.02-0.04 mg/mL NS:
34
20 mg 6 h RT, 18 h F
34 34 34
(Teva/Novopharm) shake well **(PFL) NS, sodium lactate
(RT)(PFL) sodium lactate:
34 34
no preservative 6 h RT, F

Status)
mitoXANTRONE
35 35 35
20 mg/10 mL N/A 2 mg/mL discard unused NS, D5W 24 h RT
35
(Fresenius Kabi) portion
(RT) Greater than or equal
35 35
no preservative to *50 mL
mitoXANTRONE
36 36 36
20 mg/10 mL N/A 2 mg/mL discard unused 0.2-0.6 mg/mL NS: 24 h F, RT
36
25 mg/12.5 mL portion
36 36
(Hospira) NS, D5W **(PFL)
(RT)(PFL)
36
no preservative Greater than or equal
36
to *50 mL
mitoXANTRONE
37 37
20 mg/10 mL N/A 2 mg/mL discard unused Greater than or equal 24 h RT
37 37
(Teva/Novopharm) portion to *50 mL NS, D5W
38
(RT)(PFL) **(PFL)
37
no preservative
Nivolumab
39
40 mg/4 mL N/A 10 mg/mL discard unused 1-10 mg/mL NS, complete - administer with a
39 39
100 mg/10 mL portion D5W administration within 0.2 to 1.2 micron
39 39
(BMS) 8 h RT or 24 h F in-line filter
(F)(PFL) (50-100* mL) - discard if cloudy
39
do not shake **(PFL) or has pronounced
39
no preservative mix by gentle colour change
inversion; do not (should be clear to
39 39
shake pale yellow)

Status)
oBINutuzumab
40 40,41
1000 mg/40 mL N/A 25 mg/mL discard unused 100 mg: 24 h F, 48 h RT -once removed
2 40
(Hoffman-La Roche) portion in 100 mL NS from the fridge,
**
(F)(PFL) diluted product is
do not shake 900 mg: stable for an
40 40
no preservative in 250 mL NS additional 48 h
40,41
RT
40
1000 mg: - do NOT shake
40
in 250 mL NS - do NOT use
dextrose containing
40
solutions
Octreotide
42 42 42 42
50 mcg/mL N/A 50 mcg/mL Use within 4 h NS 24 h RT
100 mcg/mL
42
500 mcg/mL 100 mcg/mL volume adjusted to
(Omega) ensure a continuous
42
(F)(PFL) 500 mcg/mL infusion of octreotide
42 42
no preservative at 25 mcg/hour
Octreotide
42 42 42 42
multidose vial: N/A 200 mcg/mL 15 d F NS 24 h RT
1000 mcg/5 mL
(Omega) volume adjusted to
(F)(PFL) ensure a continuous
42
preservative infusion of octreotide
42
at 25 mcg/hour

Status)
Octreotide
43 43 43
50 mcg/mL N/A 50 mcg/mL discard unused SC syringe use within 4 h
43
100 mcg/mL portion
43
500 mcg/mL 100 mcg/mL
(Teva/Novopharm)
43 43 43
(F)(PFL) 500 mcg/mL infusion: NS 24 h RT
43
no preservative
Octreotide
43 43,44 43,44
multidose vial: N/A 200 mcg/mL 14 d F SC syringe use within 14 d F
1000 mcg/5 mL
(Teva/Novopharm)
43 43
(F)(PFL) infusion: NS 24 h RT
43
preservative
Octreotide
45 11,47,48 47
(SANDOSTATIN®) N/A 200 mcg/mL discard unused 50–200 mL NS 24 h RT
46
1000 mcg/5 mL portion
(Novartis) SC infusion: adjust
(F)(PFL) volume to ensure
45
preservative infusion rate of 25
47
mcg/h

Status)
Octreotide
11,48 47
(SANDOSTATIN®) N/A 50 mcg/mL discard unused 50-100 mL 24 h RT
47
50 mcg/1 mL 100 mcg/mL portion
45 47
100 mcg/1 mL 500 mcg/mL NS
500 mcg/1 mL
(Novartis) SC infusion: adjust
(F)(PFL) volume to ensure
45
no preservative infusion rate of 25
47
mcg/h
Octreotide
(SANDOSTATIN LAR®) 2 mL supplied 10 mg: 5 mg/mL discard unused deep intragluteal use within 4 h of initial - do NOT shake
47 47 7,47
10 mg diluent portion administration only reconstitution
20 mg 20 mg: 10 mg/mL
30 mg gently run 2 mL
47
(Novartis) down sides of the 30 mg: 15 mg/mL
(F)(PFL) vial; do NOT disturb
46
no preservative for 2–5 min, then
47
swirl moderately
record time of
reconstitution

Status)
oFAtumumab
49 49 49
100 mg/ 5 mL N/A 20 mg/mL discard unused 1000 mL NS 48 h RT - administer with
2
1000 mg/50 mL portion 0.2 micron in-line
49
(GlaxoSmithKline) or filter
(F)(PFL) - do NOT shake;
49
no preservative alternatively, 2000 mg mix by slow
doses may be inversion to avoid
49
supplied in formation of foam
49
2 x 500 mL NS - solution may
contain a small
withdraw volume quantity of drug
from bag equal to particles; do not
volume of drug to be administer if
49
added solution is cloudy
49
or discoloured
Olaratumab
50 50
500 mg/50 mL N/A 10 mg/mL discard unused dilute to a final complete - do NOT shake
2,50
(Lilly) portion volume of 250 mL administration within
50
(F)(PFL) NS 24 h F, plus an
50
do not shake additional 12 h RT
50
no preservative do NOT use D5W or
other dextrose
50
containing solutions
50
gently invert to mix

Status)
Oxaliplatin
51
50 mg 50 mg: 5 mg/mL discard unused 250-500 mL D5W 0.2-2 mg/mL: - do NOT use
51 51 51 51
100 mg 10 mL SWI, D5W portion (0.2-0.7 mg/mL) 24 h F aluminum-
(Actavis) containing needle,
51
(RT)(PFL) 100 mg: do NOT use NS or syringe or tubing
51 51
no preservative 20 mL SWI, D5W other chloride-
51
do NOT use
aluminum-containing
51
needle and syringe
Oxaliplatin
52
50 mg/10 mL N/A 5 mg/mL discard unused 250-500 mL D5W 0.2-0.4 mg/mL: - do NOT use
52
100 mg/20 mL portion 24 h RT aluminum-
52
200 mg/40 mL (0.2-0.7 mg/mL or containing needle,
52
(Hospira/Pfizer) 5 d F plus an syringe or tubing
52,54
(RT) do NOT use NS or additional 8 h RT
52
no preservative other chloride-
53
containing solutions 0.5–2 mg/mL:
24 h RT
do NOT use or
aluminum-containing 14 d F plus an
53 52,54
needle and syringe additional 8 h RT

Status)
Oxaliplatin
55 55
50 mg/10 mL N/A 5 mg/mL discard unused 250–500 mL D5W 0.2-1.3 mg/mL: - do NOT use
55 4,56,57
100 mg/20 mL portion 48 h RT, 14 d F aluminum-
55,56
200 mg/40 mL (0.2-2 mg/mL) containing needle,
55
(sanofi-aventis) 1.3-2 mg/mL: syringe or tubing
55
(RT)(PFL) do NOT use NS or 24 h RT, 48 h F
55
55
do NOT use
aluminum-containing
55
needle and syringe
Oxaliplatin
53 2,58 53
50 mg/10 mL N/A 5 mg/mL 2 d F, RT 0.2-0.7 mg/mL 0.2-2 mg/mL:
53
100 mg/20 mL 24 h RT, 48 h F
53
150 mg/30 mL 250-500 mL D5W
200 mg/40 mL
(Sandoz) do NOT use NS or
(RT)(PFL) other chloride-
53 53
no preservative containing solution
do NOT use
aluminum-containing
53
needle and syringe

Status)
Oxaliplatin
59
50 mg/10 mL N/A 5 mg/mL discard unused 250-500 mL D5W 0.2-2 mg/mL: - do NOT use
59 59
100 mg/20 mL portion 24 h RT, 48 h F aluminum-
59
200 mg/40 mL (0.2-0.7 mg/mL) containing needle,
59
(Teva) syringe or tubing
(RT)(PFL) do NOT use NS or
59
59
containing solution
do NOT use
aluminum-containing
59
needle and syringe
PACLitaxel
60
30 mg/5 mL N/A 6 mg/ mL 30 mg: 0.3-1.2 mg/mL in NS, complete - use non-DEHP
2,60 60
100 mg/16.7 mL 48 h RT D5W, D5NS, D5LR administration within bag and tubing with
60
300 mg/50 mL 27 h RT 0.22 micron in-line
60
(Accord) 100 mg: (e.g., 100-1000 mL)* filter
2,60
(RT)(PFL) 48 h RT - avoid excessive
60 60
no preservative shaking
300 mg:
60
24 h RT

Status)
PACLitaxel
62 2,63
30 mg/5 mL N/A 6 mg/mL 48 h RT 0.3-1.2 mg/mL in NS, complete - use non-DEHP
62
100 mg/16.7 mL D5W administration within bag and tubing with
62,64
62
(Biolyse) (e.g., 100-1000 mL)* filter
61
(RT)
62
no preservative
65 65
0.1 mg/mL in NS 44 h F, RT
64
0.012-0.12 mg/mL in 16 h RT
66
NS
devices with spikes

(e.g., chemo
dispensing pins) may
67
be used with vials
PACLitaxel
69 2,69,70
30 mg/5 mL N/A 6 mg/mL 48 h RT 0.3-1.2 mg/mL in NS, complete - use non-DEHP
69
100 mg/16.7 mL D5W, D5NS, D5LR administration within bag and tubing with
69
69
300 mg/50 mL (e.g., 100-1000 mL)* filter
(Hospira)
(RT)(PFL)
68
preservative

Status)
PACLitaxel,
71 71
nanoparticle, albumin- 20 mL NS 5 mg/mL use immediately in empty sterile PVC, 48 h F plus an - each vial contains
72
bound (nab) (RT) or non-PVC, or non- additional 8 h RT 900 mg human
71 71 71
100 mg - slowly direct 8hF DEHP infusion bag albumin
(Celgene) diluent against side - to prevent
71
(RT)(PFL) of vial (i.e., greater **(PFL) foaming, do NOT
71
no preservative than or equal to 1 inject NS directly
71
min) during onto the powder
71
reconstitution - some settling may
occur; use mild
- let stand for agitation to
71
greater than or resuspend
equal to 5 min to wet - administer using
71
powder a 15 micron filter
ONLY
- gently swirl or (NOTE:filters with a
invert for greater pore size less than
than or equal to 2 15 microns may
71
min cause filter
73,74
blockage)
Pamidronate
75 75
30 mg/10 mL N/A 3 mg/mL discard unused Less than or equal to 24 h RT - do NOT mix with
75 75
60 mg/10 mL portion 0.36 mg/mL NS, calcium containing
75 75
90 mg/10 mL D5W solutions
75
(Fresenius Kabi) 6 mg/mL
(RT)
75
no preservative
75
9 mg/mL

Status)
Pamidronate
76
30 mg/10 mL N/A 3 mg/mL discard unused 0.06–0.36 mg/mL in 24 h F followed by 24 h - do NOT mix with
76 76 76
60 mg/10 mL portion NS, D5W RT (total 48 h) calcium containing
90 mg/10 mL solution (e.g.,
76 76 76
(Hospira) 6 mg/mL **(PFL) Ringer’s)
(RT)
76
no preservative
76
9 mg/mL
Pamidronate
77 77
30 mg/10 mL N/A 3 mg/mL discard unused 0.06–0.36 mg/mL in 24 h F followed by 24 h - do NOT mix with
77 77 77
77 77 77
(Omega) 6 mg/mL **(PFL) Ringer’s)
(RT)
77
no preservative
77
9 mg/mL
Pamidronate
78
30 mg/10 mL N/A 3 mg/mL discard unused 0.06-0.36 mg/mL in 24 h F followed by 24 h - do NOT mix with
78 78 78
78 78 78
(Pfizer) 6 mg/mL **(PFL) Ringer’s)
(RT)
78
no preservative
78
9 mg/mL

Status)
Pamidronate
79 79 79
30 mg/10 mL N/A 3 mg/mL discard unused NS; D5W 24 h RT - do NOT mix with
44,79
60mg/10 mL portion calcium containing
79 79
(Sandoz Canada) 6 mg/mL Ringer’s)
RT
79
no preservative
79
9 mg/mL
PANitumumab
80 80,81
100 mg/5 mL N/A 20 mg/mL discard unused Less than or equal to 24 h F, 6 h RT - administer with
80
400 mg/20 mL portion 1000 mg: 0.2 or 0.22 micron
80 80
(Amgen) 100 mL NS in-line filter
(F)(PFL) - solution may
do not shake Greater than 1000mg: contain particulates
80 80
no preservative 150 mL NS which do not affect
80
product quality
80,81
1-10mg/mL - do not administer
80
if discoloured

Status)
pegaspargase
82 82
(pegylated N/A 750 units/mL discard unused IM: syringe: - do NOT shake
82
asparaginase E. coli) portion max volume: use within 4 h of vial
2,82
3750 units/5 mL 2 mL in children and puncture
(Shire) adolescents;
(F)(PFL) 3 mL in adults
do not shake
82
no preservative if volume greater than
above, use multiple
82
sites
IV: bag:
82
100 mL NS, D5W use within 4 h of vial
2,82
puncture
Pembrolizumab
83
100 mg/4 mL N/A 25 mg/mL discard unused 1-10 mg/mL complete - use a 0.2 to 5
2,83 83
(Merck) portion NS, D5W administration within micron in-line
83 83
(F)(PFL) 6 h RT, 24 h F filter
do not shake mix by gentle - allow vials and
83 83
no preservatives inversion diluted solutions to
come to RT prior to
83
use
- vials contain 0.25
83
mL overfill

Status)
Pembrolizumab
83 83 83
50 mg 2.3 mL SWI 25 mg/mL 6 h RT, 24 h F 1-10 mg/mL NS, complete - use 0.2 to 5
83
(Merck) D5W administration within 6 micron in-line
83 84
(F) direct diluent against h RT, 24 h F filter
83
no preservative side of vial during mix by gentle - allow
83
reconstitution to inversion reconstituted vials
83
avoid foaming and diluted
solutions to come
83
allow up to 5 to RT prior to use
minutes for bubbles - vials can be at RT
83
to clear for up to 24 h prior
83
to use
83
do NOT shake - vials contain 20%
83
overfill
Pemetrexed
85 85 85
100 mg 100 mg: 25 mg/mL 24 h F, RT 100 mL 24 h F, RT - do NOT mix with
500 mg 4.2 mL preservative- preservative-free calcium containing
85 85
(Eli Lilly) free NS NS solution (e.g.,
86
(RT) Ringer’s)
85
no preservative 500 mg:
20 mL preservative-
85
free NS
PERTuzumab
87 87 87
420 mg/14 mL N/A 30 mg/mL discard unused 250 mL NS only 24 h F, RT - do NOT use
2,87
(Roche) portion dextrose containing
87 87
(F)(PFL) do NOT shake mix by gentle solutions
87
no preservative inversion to avoid
87
foaming

Status)
Plerixafor
88 88 44,89
24 mg/1.2 mL N/A 20 mg/mL discard unused SC syringe 48 hours RT
88
(sanofi-aventis) portion
(RT)
88
no preservative
Porfimer
90 90
15 mg 15 mg: 2.5 mg/mL 24 h F syringe use within 4 h of initial - avoid contact with
90 7,91
75 mg 6.6 mL D5W reconstitution skin and eyes;
90
(Axcan) **(PFL) protect exposed
90 90
(RT)(PFL) 75 mg: **(PFL) area from light
90 90
no preservative 31.8 mL D5W
record time of
reconstitution
Raltitrexed
92 92 92 92
2 mg 4 mL SWI 0.5 mg/mL 24 h F, RT 50–250 mL NS, 24 h F, RT
92
(Hospira) D5W
(F, RT)(PFL)
92
no preservative
Ramucirumab
93 93 93
100 mg/10 mL N/A 10 mg/mL discard unused 250 mL* NS 4 h RT, 24 h F - use 0.22 micron
93 93
500 mg/50 mL portion filter
94
(Eli Lilly) (0.4 – 4 mg/mL) - do NOT use
(F)(PFL) dextrose containing
93 93
(do not shake) gently invert to mix solutions
93
no preservative
93
do NOT shake

Status)
riTUXimab
95 96,97
100 mg/10 mL N/A 10 mg/mL discard unused 1-4 mg/mL NS, 24 h F, 12 h RT - once removed
95 95
500 mg/50 mL portion D5W from the fridge,
(Roche) compounded
(F)(PFL) (e.g., 250-500 mL)* product is stable
95 96,97
no preservative for 12h RT
riTUXimab
98 98 98
subcutaneous N/A 120 mg/mL discard unused SC syringe 48 h F plus 8 h RT - contains
98 98
1400 mg/11.7 mL portion hyaluronidase
1600 mg/13.4 mL - formulations are
(Roche) NOT
98
(F)(PFL) interchangeable
98
no preservative
romiDEPsin
99 99 99 99
10 mg 2.2 mL of supplied 5 mg/mL 8 h RT 500 mL NS 24 h RT - reconstituted
99,100
(Celgene Inc.) diluent solution will be
99 101
(RT) slightly viscous
2 99
no preservative swirl gently to mix - vials contain
overfill to allow for
full drug recovery
(drug vial contains
11 mg romidepsin;
diluent vial
contains 2.4 mL
99
diluent)

Status)
Siltuximab
102 102 102
100 mg 100 mg: 20 mg/mL 2 h RT 250 mL D5W complete - use 0.2 micron in-
102 102
400 mg 5.2 mL SWI administration within line filter
102
(Janssen) dilute to 250 mL final 6 h RT
(F)(PFL) 400 mg: volume by
102 102
no preservative 20 mL SWI withdrawing volume
from bag equal to
allow vial to come to volume of drug to be
102
room temperature added
prior to use (~30
102
minutes)
gently swirl, do NOT

102
shake
Streptozocin
103 103 103 103
1g 9.5mL NS, SWI, 100 mg/mL 48 h F, 24 h RT syringe 48 h F, 24 h RT
103
(Pfizer) D5W
(F)(PFL)
103 103
no preservative 50-500 mL* NS, 48 h F, 24 h RT
103
D5W, SWI
Temsirolimus
104,105 104,105 104,105
30 mg/1.2 mL 1.8 mL supplied 10 mg/mL 24 h RT 250 mL NS complete - use non-DEHP
104,105
(Wyeth) diluent administration within 6 bag and tubing with
104,105 104 104,105 104,105
(F)(PFL) **(PFL) h in-line filter
106
no preservative

Status)
Teniposide
107
50 mg/5 mL N/A 10 mg/mL discard unused 50 – 500 mL NS or 0.1-0.4 mg/mL: 24 h - do not refrigerate
107
(BMS) portion D5W for a final RT - use non-DEHP
107
(RT) concentration of 0.1-1 bag and tubing
107 107
preservative mg/mL 1 mg/mL: complete - do not use if
107,108
administration within 4 precipitates
h of preparation - contains DMA***
107,108
RT - excessive
agitation may
cause
107
precipitation
Thiotepa
109 109 109
15 mg 15 mg: 10 mg/mL 8hF reconstituted solution 4 h RT, 24 h F - do not use if
109
100 mg 1.5 mL SWI is hypotonic and must precipitates are
109
(Adienne) be further diluted with present
109
(F) 100 mg: NS prior to use - reconstituted
109 109
no preservative 10 mL SWI solution may be
doses ≤ 500 mg: used if
109
to remove haze, 500 mL NS or with an opalescent
filter through 0.22 appropriate volume to - administer with
micron filter after achieve 0.5-1 mg/mL 0.2 micron inline
110 109 109
reconstitution concentration filter
record time of doses > 500 mg:

109
reconstitution 1000 mL NS

Status)
Thiotepa
109 109 2,29
IT injection diluents containing 10 mg/mL 8hF qs to 6 mL with use within 4 h of initial - auxiliary info :
2
15 mg preservatives should preservative free reconstitution “IT”
112
100mg NOT be used for NS - label to include
(Adienne) intrathecal route in full (i.e.,
111
(F) administration INTRATHECAL
109
no preservative injection) attached
15 mg: to both syringe and
109 2
1.5 mL SWI outer ziplock bag
- do not use if
100 mg: precipitates are
109 109
10 mL SWI present
- reconstituted
to remove haze, solution may be
filter through 0.22 used if
109
micron filter after opalescent
110
reconstitution
record time of
reconstitution
Thyrotropin alfa
113 113 113 113 113
1.1 mg 1.2 mL SWI 0.9 mg/mL 24 h F syringe 24 h F
(Genzyme)
113
(F)(PFL) swirl contents
113
no preservative
do NOT shake

Status)
Topotecan
114 114 114
4 mg N/A 1 mg/mL discard unused 0.02–0.5 mg/mL 24 h F, RT
115
(Hospira) portion
(F)(PFL) 50-100 mL NS,
114 115
no preservative D5W
Topotecan
116 116 116 116 116
4 mg 4 mL SWI 1 mg/mL 24 h F, RT 0.02 – 0.5 mg/mL 24 h F, RT
(Mylan)
(RT)(PFL) 50-100 mL NS,
116 116
no preservative D5W
Topotecan
117 117
4 mg/4 mL N/A 1 mg/mL discard unused 0.02-0.5 mg/mL 24 h F
117
(Sandoz) portion
117
(F)(PFL) 50-100 mL NS, **(PFL)
117 117
no preservative D5W
Trastuzumab
118 2 118 118 118
(HERCEPTIN®) 20 mL supplied 21 mg/mL 14 d F 250 mL NS only 24 h F, RT - do NOT shake
118
440 mg BWI
(Roche) do NOT use dextrose
118
(F) swirl vial gently; containing solutions
118
preservative allow to stand
undisturbed for 5
118
min

Status)
Trastuzumab
119 119 119
Emtansine 100 mg vial: 20 mg/mL 24 h F 250 mL NS or 0.45% 24 h F - do not use if
119
(KADCYLA®) 5 mL SWI sodium chloride only reconstituted
119 119 119
100 mg do NOT freeze do NOT freeze solution contains
160 mg 160 mg vial: visible particulates
119 119
(Roche) 8 mL SWI do NOT shake or is cloudy or
119
(F)(PFL) discolored
119
no preservative swirl gently until - dextrose 5%
completely dissolved solutions cause
aggregation of the
119
do NOT shake protein; do not
dilute with dextrose
containing
119
solutions
- use a 0.2 micron
in-line filter or 0.22
micron
polyethersulfane
(PES) filter to
administer
infusions prepared
in NS; filter is
optional for
solutions in 0.45%
119
NS

Status)
TRC105 (Carotuximab)
120 121
100 mg/4 mL N/A 25 mg/mL discard unused 0.6 – 10 mg/mL NS complete infusion - use a 0.2 micron
2
200 mg/8 mL portion within 8 h RT, 24 h in-line filter for
120,121 120
400 mg/16 mL invert gently to mix F administration
(Tracon)
(F)(PFL)
120
no preservative
Treosulfan
122 7,122 123 7,122
1g pre-heat SWI to 50 mg/mL 48 h RT undiluted 48 h RT - compatible with
5g 30°C (not higher) polytetrafluoroethyl
122
(medac) shake vial carefully dilute with NS or D5W ene filters
(RT) before adding the in empty infusion bag - may require
122
no preservative warmed SWI for final concentration vigorous shaking to
122 122
1 g vial: 20 mL SWI, = 20 mg/mL reconstitute
while slightly
shaking vial and
syringe; continue
shaking the
reconstituted
solution for another
122
2 min
5 g vial: 100 mL
SWI, while slightly
shaking vial and
syringe; continue
shaking the
reconstituted
solution for another
122
2 min

Status)
vinBLAStine
124 125 126,127
10 mg/10 mL N/A 1 mg/mL discard unused 25-50 mL NS, D5W 24 h F, RT - auxiliary info:
124
(Hospira) portion WARNING: FOR
(F)(PFL) INTRAVENOUS
124
no preservative USE ONLY –
FATAL IF GIVEN
BY OTHER
128,129
ROUTES
vinBLAStine
130
10 mg/10 mL N/A 1 mg/mL discard unused 25-50 mL NS, use within 4 h of initial - auxiliary info:
130 125,131 2
(Teva) portion D5W puncture WARNING: FOR
(F)(PFL) INTRAVENOUS
130
no preservative USE ONLY –
FATAL IF GIVEN
BY OTHER
128,129
ROUTES

Status)
vinCRIStine
132 132 132 132
2 mg/2 mL N/A 1 mg/mL 8 h F, RT 50 mL* NS, D5W 24 h F, 6 h RT - auxiliary info:
5 mg/5 mL WARNING: FOR
132
(Hospira) **(PFL) INTRAVENOUS
(F)(PFL) USE ONLY –
132
no preservative FATAL IF GIVEN
BY OTHER
128,129
ROUTES
- for ULYEPOCHR
protocol, see entry
for EPOCHR
(3-in-1 solution
containing
etoposide,
DOXOrubicin,
vinCRIStine)

Status)
vinCRIStine
133 133 133
1 mg/1 mL N/A 1 mg/mL 8 h F, RT 0.01-0.1 mg/mL NS, 24 h F, RT - auxiliary info:
133
2 mg/2 mL D5W WARNING: FOR
5 mg/5 mL INTRAVENOUS
(Teva) 25-50 mL NS, D5W
134
USE ONLY –
(F)(PFL) FATAL IF GIVEN
133
no preservative BY OTHER
128,129
ROUTES
- for ULYEPOCHR
protocol, see entry
for EPOCHR
(3-in-1 solution
containing
etoposide,
DOXOrubicin,
vinCRIStine)
Vinorelbine
135 135 135
10 mg/1 mL N/A 10 mg/mL discard unused 0.5-2.0 mg/mL 24 h F, RT - auxiliary info:
135
50 mg/5mL portion WARNING: FOR
(Fresenius Kabi) NS, D5W, ½NS, INTRAVENOUS
(F)(PFL) D5½NS, Ringer’s, USE ONLY –
135 135
no preservative Ringer’s Lactate FATAL IF GIVEN
BY OTHER
128,129
ROUTES

Status)
Vinorelbine
136 136 136
10 mg/1 mL N/A 10 mg/mL discard unused 0.5–2.0 mg/mL 24 h F, RT - auxiliary info:
136
50 mg/5 mL portion WARNING: FOR
(Hospira) 50 mL* NS, D5W, INTRAVENOUS
(F)(PFL) ½NS, D5½NS, USE ONLY –
136
no preservative Ringer’s, Ringer’s FATAL IF GIVEN
136
Lactate BY OTHER
128,129
ROUTES
Vinorelbine
137 137 137
10 mg/1 mL N/A 10 mg/mL discard unused 0.5–2.0 mg/mL 24 h F, RT - auxiliary info:
137
50 mg/5 mL portion WARNING: FOR
(Teva) 50 mL* NS, D5W, INTRAVENOUS
(F)(PFL) ½NS, D5½NS, USE ONLY –
137
no preservative Ringer’s, Ringer’s FATAL IF GIVEN
137
Lactate BY OTHER
128,129
ROUTES
Zoledronic acid
138 138
4 mg/5 mL N/A 0.8 mg/mL discard unused 100 mL NS, D5W complete infusion - do NOT mix with
138
(Dr Reddy’s) portion within 24 h of calcium containing
138 138
(RT) preparation solutions
138
no preservative
Refrigerate diluted
product if not used
immediately after
preparation; bring to
RT prior to
138
administration

Status)
Zoledronic acid
139 139
4 mg/5 mL N/A 0.8 mg/mL discard unused 100 mL NS, D5W complete infusion - do NOT mix with
139
(MDA) portion within 24 h of calcium containing
139 139
(RT) preparation solutions
139
no preservative
Refrigerate diluted
product if not used
immediately after
RT prior to
139
administration
Zoledronic acid
140 140
(ZOMETA) N/A 0.8 mg/mL discard unused 100 mL NS, D5W complete infusion - do NOT mix with
2
4 mg/ 5 mL portion within 24 h of calcium containing
140 140
(Novartis) preparation solutions
(RT)
140
no preservative Refrigerate diluted
product if not used
immediately after
RT prior to
140
administration

Status)
Zoledronic acid
141 141
4 mg/5 mL N/A 0.8 mg/mL discard unused 100 ml NS, D5W complete infusion - do NOT mix with
141
(Sandoz) portion within 24 h of calcium- or other
141
(RT) preparation divalent cation-
141
no preservative containing infusion
Refrigerate diluted solutions (e.g.,
product if not used Lactated
141
immediately after Ringer’s)
RT prior to
141
administration
* Suggested volume based on usual dose range and any concentration range of stability data
** Protect from light means minimizing exposure to direct sunlight over a storage period. More specific information on protection from light (eg, protecting container and tubing during
administration) will be indicated in the Under the Special Precautions/Notes column.
*** Contains DMA (N,N dimethylacetamide). Product may be incompatible with closed system transfer devices such as ChemoLock.
Centres are not to change the content locally but should forward suggestions to the Cancer Drug Manual staff.
Explanatory Notes
Stability data assumes products prepared using standard aseptic technique in biological safety cabinet at low risk for contamination according to the classification
142,143
outlined in USP 797.
Vial stability: Stability of solution after first puncture or reconstituted solution.
Storage temperature: If information states same stability with refrigerator and room temperature storage, then fridge stability is bolded as preferred (ie, to minimize
growth of micro-organisms).
Discard unused portion: Unused portion from single use vials should be discarded at the end of the day.
“overfill known” is stated if the manufacturer states overfill that is present is within acceptable limits.
“Complete administration within __” is stated if the manufacturer specifies that the infusion must be completed in a specific time frame following preparation,
usually including entire time required for preparation (from first puncture), storage, and administration of infusion.

Abbreviations
BWI = bacteriostatic water for injection
CIVI: ambulatory pump = Continuous Intravenous Infusion (e.g., elastomeric infusor)
D5W = dextrose 5% in water
DMA = N,N dimethylacetamide
F = refrigerate
Non-DEHP = not containing Di(2-ethylhexyl) phthalate (DEHP)
NS = normal saline
PFL = protect from light
RT = room temperature
SWI = sterile water for injection
References
1. Hospira Healthcare Corporation. LEUCOVORIN CALCIUM INJECTION® product monograph. Saint-Laurent, Quebec; 7 June 2007.
2. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September 2007.
3. John Korontzis. Personal communication. Regulatory Affairs Associate, Leucovorin Calcium, Mayne Pharma Canada; February 2005.
4. The United States Pharmacopeial Convention, Inc. General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United
States Pharmacopeial Convention, Inc.; 2003.
5. Teva Canada Limited. Leucovorin calcium injection® product monograph. Toronto, Ontario; 5 May 2014.
6. Novopharm Limited (Teva). LEUCOVORIN CALCIUM® Injection product information package. Toronto, Ontario; undated.
7. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 6 January 2006.
8. Jenny Yeung. Personal communication. Medical Information Specialist, Teva Canada; 12 April 2017.
9. Pfizer Canada Inc. Leucovorin calcium injection product monograph. Kirkland, Quebec; 21 June 2018.
10. Ovation Pharmaceuticals Inc. MUSTARGEN® Package Insert. Deerfield, Illinois; October 2005.
11. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2005.
12. Trissel LA. Handbook on Injectable Drugs. 12th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2003.
13. GlaxoSmithKline Inc. Alkeran Package Insert. Mississauga, Ontario; Montreal, Quebec; 2004.
14. Baxter Corporation. UROMITEXAN® product monograph. Mississauga, Ontario; 6 August 2013.
15. Mona Ghobros BPharm MSc. Personal communication. Medical Information, Baxter Corporation; 29 November 2018.
16. Trissel's® 2 Clinical Pharmaceutics Database (database on the Internet). Mesna. Lexi-Comp Inc.; created by Lawrence A. Trissel, Available at: http://online.lexi.com. Accessed 29
November 2018.
17. Fresenius Kabi Canada Ltd. Mesna for injection product monograph. Richmond Hill, Ontario; 21 December 2017.
18. BC Cancer. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer; 19 September 2007.
19. Fresenius Kabi Canada Ltd. Mesna for injection product monograph. Richmond Hill, Ontario; 30 March 2015.
20. Pfizer Canada Inc. Methotrexate injection product monograph. Kirkland, Quebec; 13 October 2017.
21. BC Cancer Agency Miscellaneous Origins Tumour Group. (MOHDMTX) BCCA Protocol Summary for Treatment of Meningeal Disease (Miscellaneous Tumour Origins) using High
Dose Methotrexate with Leucovorin Rescue. Vancouver, British Columbia: BC Cancer Agency; 1 Jan 2013.
22. BC Cancer Agency Sarcoma Tumour Group. (SAHDMTX) BCCA Protocol Summary for Treatment of Osteosarcoma Using High Dose Methotrexate with Leucovorin Rescue.
Vancouver, British Columbia: BC Cancer Agency; 1 Nov 2012.
23. BC Cancer Agency Lymphoma Tumour Group. (LYHDMRP) BCCA Protocol Summary for Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate and
riTUXimab. Vancouver, British Columbia: BC Cancer Agency; 1 Jun 2014.

24. BC Cancer Agency Lymphoma Tumour Group. (LYHDMTXP) BCCA Protocol Summary for Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate.
Vancouver, British Columbia: BC Cancer Agency; 1 Jun 2014.
25. BC Cancer Agency Lymphoma Tumour Group. (LYHDMTXR) BCCA Protocol Summary for Treatment of Leptomeningeal Lymphoma or Recurrent Intracerebral Lymphoma with
High Dose Methotrexate. Vancouver, British Columbia: BC Cancer Agency; 1 Jun 2014.
26. Mayne Pharma Canada. Methotrexate Product Monograph. Montreal, Quebec; December 2003.
27. BC Cancer Lymphoma Tumour Group. (LYIT) BC Cancer Protocol Summary for Treatment of Lymphoma using Intrathecal Methotrexate and Cytarabine. Vancouver, British
Columbia: BC Cancer; 1 June 2014.
28. BC Cancer Miscellaneous Origin Tumour Group. (MOIT) BC Cancer Protocol Summary for Solid Tumours using Intrathecal Methotrexate and/or Thiotepa and/or Cytarabine.
Vancouver, British Columbia: BC Cancer; 1 October 2018.
29. BC Cancer. Systemic Therapy Policy III-50: Administration of Hazardous Drugs by the Intrathecal Route via Lumbar Puncture or Ommaya Reservoir. Vancouver, British Columbia;
1 November 2012.
30. Accord Healthcare Inc. Mitomycin product monograph. Kirkland, Quebec; 7 June 2017.
31. Au JLS, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001;93(8):597-
604.
32. Jessie LS Au PharmD PhD. Personal communication. Distinguished University Professor, The Ohio State University; 14 May 2007.
33. Myers AL, Zhang Y, Kawedia JD, et al. Solubilization and stability of mitomycin C solutions prepared for intravesical administration. Drugs R D 2017;17:297-304.
34. Teva Canada Limited. Mitomycin for injection® product monograph. Toronto, Ontario; 30 June 2017.
35. Fresenius Kabi Canada Ltd. Mitoxantrone injection® product monograph. Richmond Hill, Ontario; 28 September 2016.
36. Hospira Healthcare Corporation. Mitoxantrone Injection, USP Product Monograph. Saint-Laurent, Quebec; 13 June 2007.
37. Novopharm Limited. Mitoxantrone Injection Product Monograph. Toronto, Ontario; 19 May 2005.
38. Angie Chan. Personal communication. Drug Information Pharmacist, Novopharm; 7 Mar 2008.
39. Bristol-Myers Squibb Canada. OPDIVO® product monograph. Montreal, Quebec; 16 July 2018.
40. Hoffmann-La Roche Ltd. GAZYVA® product monograph. Mississauga, Ontario; 21 December 2015.
41. Anna Sivojelezova MSc. Personal communication. Drug Information Associate; Hoffmann-La Roche Ltd Drug Information; 24 April 2015.
42. Omega Laboratories Ltd. Octreotide Acetate Injection product monograph. Montreal, Quebec; 23 July 2010.
43. Novopharm Limited. Octreotide Injection Product Monograph. Scarborough, Ontario; 15 March 2007.
44. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September
2007.
45. Novartis Pharmaceuticals Canada Inc. SANDOSTATIN® Product Monograph. Dorval, Quebec; 9 January 2001.
46. Repchinsky C, editor. Sandostatin LAR monograph, Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario: Canadian Pharmacists Association; 2005. p. 1912-1916.
47. Repchinsky C editor. Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association; 2004.
48. Vancouver Hospital and Health Sciences Centre Pharmacy Department. Octreotide. Parenteral drug therapy manual. Vancouver, BC; February 2002.
49. GlaxoSmithKline. Guidance Booklet: compassionate use access of ofatumumab for patients with chronic lymphocytic leukemia (CLL) who are refractory to fludarabine and
alemtuzumab or who are deemed inappropriate for alemtuzumab therapy. version 5; 1 February 2010.
50. Eli Lilly Canada Inc. LARTRUVO® product monograph. Toronto, Ontario; 23 November 2017.
51. Actavis Pharma Company. ACT Oxaliplatin® product monograph. Mississauga, Ontario; 1 June 2015.
52. Pfizer Canada Inc. Oxaliplatin injection product monograph. Kirkland, Quebec; 31 May 2017.
53. Sandoz Canada Inc. Oxaliplatin injection product monograph. Boucherville, Quebec; 12 August 2015.
54. Medical Information. Personal communication. Pfizer Canada Inc.; 6 June 2017.
55. sanofi-aventis Canada Inc. ELOXATIN® product monograph. Laval, Quebec; 13 January 2009.
56. Eiden C, Philibert L, Bekhtari K, et al. Physicochemical stability of oxaliplatin in 5% dextrose injection stored in polyvinyl chloride, polyethylene, and polypropylene infusion bags.
Am J Health Syst Pharm 2009;66.
57. Andre P, Cisternino S, Roy A-, et al. Stability of oxaliplatin in infusion bags containing 5% dextrose injection. American Journal of Health-System Pharmacy 2007;64(18):1950-
1954.
58. Katryn Vosburg. Personal communication. Drug Information & Pharmacovigilance Specialist, Sandoz Canada Inc.; 26 February 2016.
59. Teva Canada Limited. Teva-Oxaliplatin injection® product monograph. Toronto, Ontario; 11 September 2015.

60. Accord Healthcare Inc. Paclitaxel injection product monograph. Markham, Ontario; 13 August 2012.
61. Claude Mercure. Personal communication. Production Manager Biolyse Pharma Corporation; 21 December 2009.
62. Biolyse. PACLITAXEL FOR INJECTION® product monograph. St. Catherines, Ontario; 2 December 2005.
63. Claude Mercure. Personal communication. Manager, Biolyse Pharma Corporation; 24 June 2014.
64. Zeng Z, Lazakovitch E. Study IR 120: Physical and Chemical Stability Study of Paclitaxel for Injection in 0.9 % Sodium Chloride in concentration range 0.012-0.12 mg/mL. Biolyse
Pharma March 2010.
65. Mercure C. Stability of 0.1 mg/mL of paclitaxel for injection in sodium chloride (0.9%) solution. St Catharines, Ontario: Biolyse Pharma; 2 February 2007.
66. Xu Q, Trissel LA, Martinez JF. Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4, 22, or 32 degrees C. Am J Hosp Pharm 1994;51(24):3058-60.
67. Lisa Tavano. Personal communication. Biolyse Pharma Corporation; 14 May 2012.
68. Robyn MacKenzie. Personal communication. Area Manager, Hospira Healthcare Corporation; 4 April 2012.
69. Hospira Healthcare Corporation. PACLITAXEL FOR INJECTION® product monograph. Saint-Laurent, Quebec; 1 September 2009.
70. Rose Toussaint. Personal communication. Hospira Canada Healthcare Corporation; 4 April 2012.
71. Celgene Inc. ABRAXANE® product monograph. Mississauga, Ontario; 24 July 2014.
72. Aisling Cahill. Drug Safety and Medical Information Specialist. Personal communication. Celgene Inc.; 23 April 2015.
73. Celgene Europe Limited. ABRAXANE® product monograph. Uxbridge, UK; 11 January 2013.
74. Celgene Inc. ABRAXANE® product monograph. Mississauga, Ontario; 18 January 2016.
75. Pharmaceutical Partners of Canada. Pamidronate Disodium For Injection product monograph. Richmond Hill, Ontario; 18 January 2010.
76. Mayne Pharma (Canada) Inc. Pamidronate Package Insert. Montreal, Quebec; 2002.
77. Omega Laboratories Ltd. Pamidronate Disodium product monograph. Montreal, Quebec; 06 June 2005.
78. Pfizer Canada ULC. Pamidronate disodium for injection product monograph. Kirkland, Quebec; 11 December 2018.
79. Sandoz Canada Inc. Pamidronate injection product monograph. Boucherville, Quebec; 28 February 2006.
80. Amgen Canada. VECTIBIX® product monograph. Mississauga, Ontario; 5 March 2009.
81. Diane Lord. Personal communication. Amgen Canada Inc Medical Information Department; 19 June 2009.
82. Shire Pharma Canada ULC. ONCASPAR® product monograph. Toronto, Ontario; 20 April 2018.
83. Merck Canada Inc. KEYTRUDA® product monograph. Kirkland, Quebec; 21 February 2018.
84. Merck Canada Inc. KEYTRUDA® product monograph. Kirkland, Quebec; 5 February 2016.
85. Eli Lilly Canada. Pemetrexed product information. Toronto, Ontario; 2008.
86. Eli Lilly Canada Inc. ALIMTA® Product Monograph. Toronto, Ontario; 21 May 2004.
87. Hoffmann-La Roche Limited. PERJETA® product monograph. Mississauga, Ontario; 12 April 2013.
88. sanofi-aventis Canada Inc. MOZOBIL® product monograph. Laval, Quebec; 8 October 2014.
89. Maureen Coughlin BSc Pharm. Personal communication. Solutions in Health Inc. acting as an authorized agent of sanofi-aventis; 24 May 2017.
90. Axcan Pharma Inc. Photofrin Package Insert. Mont-Saint-Hilaire, Quebec; 2004.
91. Marie-Helene Doyon B.Pharm. M.Sc. Personal communication. Medical Information Specialist, Porfimer, Axcan Pharma. 3 March 2005.
92. Hospira Healthcare Corporation. TOMUDEX® product monograph. Saint-Laurent, Quebec; 23 April 2008.
93. Eli Lilly Canada Inc. CYRAMZA® product monograph. Toronto, Ontario; 16 July 2015.
94. Marilyn Bain BScN. Personal communication. Senior Medical Information Associate, Eli Lilly Canada, Inc.; 16 January 2017.
95. Hoffmann-La Roche Ltd. RITUXAN® product monograph. Mississauga, Ontario; 29 March 2012.
96. Hoffmann-La Roche Ltd. RITUXAN® product monograph. Mississauga, Ontario; 29 May 2014.
97. Diana Fung pharmacist. Personal communication. Hoffmann-La Roche Medical Information; 16 July 2014.
98. Hoffmann-La Roche Ltd. RITUXAN® SC product monograph. Mississauga, Ontario; 21 March 2018.
99. Celgene Inc. ISTODAX® product monograph. Mississauga, Ontario; 13 December 2016.
100. Celgene Inc. INFO Rx ISTODAX® (romidepsin) for Injection. Mississauga, Ontario; 10 July 2017.
101. Aisling Cahill, Drug Safety and Medical Information Specialist. Personal communication. Celgene Inc.; 17 July 2015.
102. Janssen Inc. SYLVANT® product monograph. Toronto, Ontario; 6 January 2016.
103. Pharmacia Canada Inc. Zanosar Package Insert. Mississauga, Ontario; March 2003.
104. Wyeth Canada. TORISEL® product monograph. Montreal, Canada; 16 October 2008.

105. McEvoy GK, editor. AHFS 2008 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc. p. 1226-1228.
106. Anna Sivojelezova M.Sc. Personal communication. Medical Information Associate, Wyeth. 6 January 2010.
107. Bristol-Myers Squibb Canada. VUMON® product monograph. St. Laurent, Quebec; 26 October 2004.
108. Trissel's®2 IV Compatibility (database on the Internet). Teniposide. Thomson Reuters MICROMEDEX® 2.0, updated periodically. Available at: http://www.micromedex.com.
Accessed 27 April 2011.
109. Adienne SA. TEPADINA® product monograph. Lugano, Switzerland; 28 March 2017.
110. AHFS Drug Information® (database on the Internet). Thiotepa. Lexi-Comp Inc., 27 February 2018. Available at: http://online.lexi.com. Accessed 21 August 2018.
111. Hematology/Oncology Pharmacy Association. HOPA News Clinical Pearls: Intrathecal Chemotherapy: Focus on Drugs, Dosing, and Preparation. 13(4) ed. Chicago, Illinois, USA:
Hematology/Oncology Pharmacy Association; 2016.
112. BC Cancer Agency Miscellaneous Origin Tumour Group. (MOIT) BCCA Protocol Summary for Solid Tumours using Intrathecal Methotrexate and/or Thiotepa and/or Cytarabine.
Vancouver, British Columbia: BC Cancer Agency; 1 May 2009.
113. Genzyme Canada. Thyrogen Product Monograph. Mississauga, Ontario; 2004.
114. Hospira Healthcare. Topotecan Hydrochloride for Injection product monograph. Saint-Laurent, QC; 22 June 2012.
115. Hospira Healthcare Corporation. Topotecan hydrochloride for injection product monograph. Saint-Laurent, Quebec; 26 August 2014.
116. Mylan Pharmaceuticals ULC. Topotecan hydrochloride for injection product monograph. Etobicoke, Ontario; 18 February 2015.
117. Sandoz Canada Inc. Topotecan injection product monograph. Boucherville, Quebec; 5 September 2014.
118. Hoffman-La Roche Limited. HERCEPTIN® product monograph. Mississauga, Ontario; 16 November 2012.
119. Hoffmann-La Roche Limited. KADCYLA® product monograph. Mississauga, Ontario; 11 September 2013.
120. Tracon Pharmaceuticals Inc. TRC105 (carotuximab) investigational brochure. San Diego, California; 14 February 2017 (version 10.0).
121. Tracon Pharmaceuticals Inc. Clincial Protocol: A Phase 2A Study of TRC105 (with Option to Add Bevacizumab) in Patients with Refractory Gestastional Trophoblastic Neoplasia
(GTN). San Diego, California; 20 September 2016 Amendment #3.
122. medac UK. TREOSULFAN injection® product monograph. Hamburg, Germany; 24 June 2008.
123. Henrik Fenger. Personal communication. Management Assiciate, International Division medac; 03 March 2010.
124. Mayne Pharma (Canada) Inc. Vinblastine product monograph. Kirkland, Quebec; 10 August 2003.
125. Lexi-Drugs® (database on the Internet). VinBLAStine. Lexi-Comp Inc., 3 November 2014. Available at: http://online.lexi.com. Accessed 20 November 2014.
126. Jan Barrow. Personal communication. Supervisor, Hospira Canada Clinical Support. Saint-Laurent, Quebec; 03 December 2007.
127. Tanya Leduc. Personal communication. Acting editor, BC Cancer Agency Cancer Drug Manual; 18 Dec 2007.
128. World Health Organization. Information Exchange System: Alert No. 115 (QSM/MC/IEA.115). Geneva, Switzerland: World Health Organization; 18 July 2007.
129. BCCA Provincial Systemic Therapy Program. Labeling of vinca alkaloid syringes. Policy # V-40. Vancouver, British Columbia: BC Cancer Agency; 27 May 1999.
130. Teva Canada Limited. Vinblastine sulfate injection® product monograph. Toronto, Ontario; 1 February 2013.
131. Trissel's®2 IV Compatibility (database on the Internet). Vinblastine sulfate. Thomson Reuters MICROMEDEX® 2.0, updated periodically. Available at:
http://www.micromedex.com. Accessed 8 June 2015.
132. Mayne Pharma (Canada) Inc. Vincristine Package Insert. Montreal, QC; Undated.
133. Teva Canada Limited. Vincristine sulfate injection® product monograph. Scarborough, Ontario; 27 March 2014.
134. Lexi-Drugs® (database on the Internet). VinCRIStine. Lexi-Comp Inc., 3 June 2015. Available at: http://online.lexi.com. Accessed 9 June 2015.
135. Pharmaceutical Partners of Canada. Vinorelbine Injection product monograph. Richmond Hill, Ontario; 15 January 2008.
136. Mayne Pharma (Canada) Inc. Vinorelbine Product Monograph. Montreal, QC; Undated.
137. Teva Canada Limited. Vinorelbine tartrate for Injection product monograph. Toronto, Ontario; 20 March 2014.
138. Innomar Strategies Inc. (for Dr. Reddy's Laboratories Limited). Zoledronic acid for injection concentrate® product monograph. Oakville, Ontario; 11 March 2015.
139. MDA inc. Zoledronic acid for injection product monograph. Mississauga, Ontario; 11 August 2015.
140. Novartis Pharmaceuticals Canada Inc. ZOMETA® product monograph. Dorval, Quebec; 26 July 2013.
141. Sandoz Canada Inc. Zoledronic Acid - Z® product monograph. Boucherville, Quebec; 02 December 2016.
142. The United States Pharmacopeia (USP). General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United States
Pharmacopeial Convention, Inc.; 2004.
143. Kastango ES. The ASHP discussion guide for compounding sterile preparations. Bethesda (MD): American Society of Health-System Pharmacists, Inc.; 2004. p. 5.


Chemotherapy

Uploaded by

Copyright:

Available Formats

Chemotherapy

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Chemotherapy

Uploaded by

Copyright:

Available Formats

What drugs are covered in the document?

What drugs are covered in the document?

What information is provided for each drug?

What information is provided for each drug?

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART

(e.g., 50-250 mL*) D10W, D5-NS:

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 1/39

(e.g., 50-250 mL*)

0.06 - 0.4 mg/mL NS, NS:

0.06 - 1 mg/mL Ringer’s, LR:

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 2/39

(e.g., 50-250 mL*) D10W, D5NS:

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 3/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 4/39

high dose use within 24 h RT of

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 5/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 6/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 7/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 8/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 9/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 10/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 11/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 12/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 13/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 14/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 15/39

devices with spikes

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 16/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 17/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 18/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 19/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 20/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 21/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 22/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 23/39

gently swirl, do NOT

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 24/39

record time of doses > 500 mg:

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 25/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 26/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 27/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 28/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 29/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 30/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 31/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 32/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 33/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 34/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 35/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 36/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 37/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 38/39

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 39/39

You might also like